Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. (Q42651816)

4 November 2017

Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. (English)

1 reference

4 November 2017

1 reference

1 reference

peginterferon alfa-2b

1 reference

1 reference

Stefan Wirth

1

1 reference

4 November 2017

Heidrun Pieper-Boustani

2

1 reference

4 November 2017

Thomas Lang

3

1 reference

4 November 2017

Antje Ballauff

4

1 reference

4 November 2017

Ulrike Kullmer

5

1 reference

4 November 2017

Patrick Gerner

6

1 reference

4 November 2017

Philip Wintermeyer

7

1 reference

4 November 2017

Andreas Jenke

8

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

4 November 2017

1 reference

4 November 2017

41

1 reference

4 November 2017

1013-1018

1 reference

4 November 2017

5

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

4 November 2017

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

An epidemiological survey of hepatitis C virus infection in Italian children in the decade 1990-1999.

1 reference

7 January 2021

Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children.

1 reference

7 January 2021

Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth

1 reference

7 January 2021

Is severe liver disease a common outcome for people with chronic hepatitis C?

1 reference

7 January 2021

Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission.

1 reference

7 January 2021

Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy

1 reference

7 January 2021

Quality of reporting of meta-analyses: the QUOROM statement. Will it help?

1 reference

7 January 2021

Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C?

1 reference

7 January 2021

Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C.

1 reference

7 January 2021

Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C.

1 reference

7 January 2021

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

1 reference

7 January 2021

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

7 January 2021

Use of PEG-interferon alfa-2a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL.

1 reference

7 January 2021

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening

1 reference

7 January 2021

Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values

1 reference

7 January 2021

Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study

1 reference

7 January 2021

Outcomes of interferon and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases

1 reference

7 January 2021

Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20661

1 reference

4 November 2017

1 reference